- Supplier site
- Group of sites (click to zoom)
Scientist.com supplier network (site locations)
Research supplier
Cleveland BioLabs
Cleveland BioLabs is listed as a small business research supplier in the Scientist.com network, with 1 site in 1 country.
Sign in to Scientist.com to open this supplier in your organization's marketplace.
Search companies, drugs, suppliers and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Logo Statera BioPharma, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
Services
What this research supplier says it provides, as listed in the Scientist.com network.
Type of company: Small business
Biomarkers
- Myeloperoxidase Testing Detect inflammatory markers and determine the risk for atherosclerosis or arterial plaque rupturing.
Where it operates
Sites by country, with the cities in each.
-
United States 1 site
About this supplier
In the supplier's own words, as listed in the Scientist.com network.
Cleveland BioLabs, Inc. (Nasdaq:CBLI) is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant unmet medical need. We combine our proven scientific expertise and depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our programs are focused on the implementation of novel pharmacological approaches to control cell death. Our proprietary drug candidates act via unique mechanisms and targets to kill cancer and protect healthy cells. Our lead product...
Show the full description
Cleveland BioLabs, Inc. (Nasdaq:CBLI) is an innovative biopharmaceutical company seeking to develop first-in-class pharmaceuticals designed to address diseases with significant unmet medical need. We combine our proven scientific expertise and depth of knowledge about our products’ mechanisms of action into a passion for developing drugs to save lives. Our programs are focused on the implementation of novel pharmacological approaches to control cell death. Our proprietary drug candidates act via unique mechanisms and targets to kill cancer and protect healthy cells.
Our lead product candidates are entolimod, which is being developed for a biodefense indication and as a potential cancer treatment and Curaxin CBL0137, our lead oncology product candidate. We have additional pipeline product candidates in various stages of development.
- Website
- www.cbiolabs.com
Work with Cleveland BioLabs on Scientist.com
For prices, more details, or to contact Cleveland BioLabs, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.